Literature DB >> 24261479

Preventive pharmacotherapy in migraine.

Paul Rizzoli1.   

Abstract

Migraine prevention can be instrumental in the effective management of the migraine patient but remains underused in treatment of this common, chronic, and often debilitating condition. The development of methysergide as the first migraine preventive agent not only laid the groundwork for our current thinking about migraine prevention, but also created a paradigm shift away from migraine as a psychological issue and toward migraine as a legitimate medical condition. This short review is intended to help the reader select patients appropriate for prevention and to initiate, monitor, and adjust preventive treatment. Goals in discussing preventive management are to facilitate provider familiarity with and confidence in this therapy leading to improved clinical outcomes and to a reduced burden of headache-related disability. Optimal therapeutic success is best achieved in the setting of a strong therapeutic alliance. Medication options for prevention are reviewed. Continued educational efforts directed at both patient and provider may be required to improve treatment utilization and reduce headache impact.
© 2013 American Headache Society.

Entities:  

Keywords:  methysergide; migraine; migraine therapy; pharmacotherapy; prevention; therapeutic alliance

Mesh:

Year:  2013        PMID: 24261479     DOI: 10.1111/head.12273

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  11 in total

1.  Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.

Authors:  Virginia L Stauffer; David W Dodick; Qi Zhang; Jeffrey N Carter; Jessica Ailani; Robert R Conley
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

Review 2.  Targeting CGRP: A New Era for Migraine Treatment.

Authors:  Stephanie Wrobel Goldberg; Stephen David Silberstein
Journal:  CNS Drugs       Date:  2015-06       Impact factor: 5.749

Review 3.  Inpatient management of migraine.

Authors:  Michael J Marmura; Stephanie Wrobel Goldberg
Journal:  Curr Neurol Neurosci Rep       Date:  2015-04       Impact factor: 5.081

4.  Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine.

Authors:  Scott W Powers; Christopher S Coffey; Leigh A Chamberlin; Dixie J Ecklund; Elizabeth A Klingner; Jon W Yankey; Leslie L Korbee; Linda L Porter; Andrew D Hershey
Journal:  N Engl J Med       Date:  2016-10-27       Impact factor: 91.245

Review 5.  A Comprehensive Review of Zavegepant as Abortive Treatment for Migraine.

Authors:  Nazir Noor; Alexis Angelette; Abby Lawson; Anjana Patel; Ivan Urits; Omar Viswanath; Cyrus Yazdi; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-06-28

6.  Comparison of Levetiracetam and sodium Valproate in migraine prophylaxis: A randomized placebo-controlled study.

Authors:  Homa Sadeghian; Rouzbeh Motiei-Langroudi
Journal:  Ann Indian Acad Neurol       Date:  2015 Jan-Mar       Impact factor: 1.383

Review 7.  Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.

Authors:  Vincent Martin; Karen Hamrick Samaan; Sheena Aurora; Eric M Pearlman; Chunmei Zhou; Xiaoping Li; Robert Pallay
Journal:  Adv Ther       Date:  2020-04-21       Impact factor: 3.845

8.  Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine.

Authors:  Janet H Ford; Shonda A Foster; Virginia L Stauffer; Dustin D Ruff; Sheena K Aurora; Jan Versijpt
Journal:  Patient Prefer Adherence       Date:  2018-11-13       Impact factor: 2.711

9.  InterMiG: international differences in the therapeutic approach to migraine patients in specialized headache centers.

Authors:  A B Gago-Veiga; J-I Huhn; N Latysheva; A Vieira Campos; M Torres-Ferrus; A Alpuente Ruiz; S Sacco; I Frattale; R Ornello; R Ruscheweyh; I B Marques; A Gryglas-Dworak; C Stark; V J Gallardo; P Pozo-Rosich
Journal:  J Headache Pain       Date:  2021-05-24       Impact factor: 7.277

10.  Cathodal Transcranial Direct Current Stimulation of the Occipital cortex in Episodic Migraine: A Randomized Sham-Controlled Crossover Study.

Authors:  Rechdi Ahdab; Anthony G Mansour; Georges Khazen; Christelle El-Khoury; Toni M Sabbouh; Maher Salem; Wissam Yamak; Samar S Ayache; Naji Riachi
Journal:  J Clin Med       Date:  2019-12-26       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.